Literature DB >> 18203028

Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection.

Roshan Lewis, Holly Hogan, Allan Howell, Amar Safdar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18203028     DOI： 10.1080/10428190701724819

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  10 in total

1.  Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis.

Authors:  Prithviraj Bose; Hiral D Parekh; Jennifer L Holter; Ronald A Greenfield
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

Review 2.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 3.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 4.  Fusarium infection in lung transplant patients: report of 6 cases and review of the literature.

Authors:  Herman A Carneiro; Jeffrey J Coleman; Alejandro Restrepo; Eleftherios Mylonakis
Journal:  Medicine (Baltimore)       Date:  2011-01       Impact factor: 1.889

5.  Characterization of Phase Transformations for Amorphous Solid Dispersions of a Weakly Basic Drug upon Dissolution in Biorelevant Media.

Authors:  Ahmed Elkhabaz; Sreya Sarkar; Garth J Simpson; Lynne S Taylor
Journal:  Pharm Res       Date:  2019-10-30       Impact factor: 4.200

6.  Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.

Authors:  Jeroen Walravens; Joachim Brouwers; Isabel Spriet; Jan Tack; Pieter Annaert; Patrick Augustijns
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

7.  Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease.

Authors:  Amar Safdar; Gilhen Rodriguez; Jorge Zuniga; Fadi Al Akhrass; Georgia Georgescu; Anupam Pande
Journal:  Acta Haematol       Date:  2012-10-02       Impact factor: 2.195

8.  Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.

Authors:  Mery Ruíz-Cendoya; Marçal Mariné; M M Rodríguez; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 9.  Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment.

Authors:  J Guarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-11       Impact factor: 3.267

10.  Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?

Authors:  Hillard M Lazarus; Carolyn E Ragsdale; Robert Peter Gale; Gary H Lyman
Journal:  Front Immunol       Date:  2021-08-17       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.